Get notified when FBLG files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company's auditor has issued a going-concern warning, and FibroBiologics states it will require additional financing to continue as a going concern.
- Delisting (new) — FibroBiologics received a Nasdaq delisting notice in December 2025 and regained compliance after a 1-for-20 reverse stock split, but remains under a Mandatory Panel Monitor until April 2027.
FibroBiologics launches at-the-market offering to sell up to $6.15M of common stock at $1.31 per share
Filed May 1, 2026 · ~1 min read
Key Changes
-
high
FibroBiologics may sell up to $6.15M of common stock via an at-the-market offering with H.C. Wainwright, with net proceeds to the company of $6M.
The Offering verify on EDGAR → -
medium
The company intends to use net proceeds for working capital and general corporate purposes, with broad management discretion.
Use of Proceeds verify on EDGAR → -
high
New investors will experience immediate dilution of $0.1932 per share in net tangible book value based on assumed sale of 4,694,656 shares at $1.31.
Dilution verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MRSH 10-Q) is open in full — no account needed.
Partner
Trade FBLG commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify